SMC approves Amgen ’s carfilzomib for multiple myeloma treatment
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen ’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Dexamethasone | Myeloma | National Health Service (NHS) | Pharmaceuticals | Scotland Health | UK Health